home

conference

Transcatheter Cardiovascular Therapeutics

Patrick Campbell is the assistant managing editor of Endocrinology Network, as well as its sister publications Practical Cardiology and Rheumatology Network. Prior to joining these brands, he led coverage of cardiology and diabetes with HCPLive. Before joining parent company MJH Life Sciences in 2019, he spent time as a beat reporter with the Pocono Record in Stroudsburg, PA, and Star News Group in Manasquan, NJ. He also touts experience in multimedia, having spent time as a freelance multimedia specialist with NJ Advance Media and multimedia coordinator at the Pocono Record. Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

Articles

Results of the 5-year follow-up from SURTAVI, which were presented at TCT 2021, provide insight into the associations of TAVR with mortality and stroke compared to SAVR in patients with severe aortic stenosis considered to be at intermediate risk. 

SURTAVI: TAVR Results Similar to Surgery at 5 Years

Data from the FAME 3 trial cast doubt on the role of FFR-guided PCI versus CABG among patients with 3-vessel coronary artery disease. 

FFR-Guided PCI Fails to Prove Noninferiority to CABG in FAME 3

Videos

Practical Cardiology advisory board member Tsuyoshi Kaneko, MD, reflects on 3 studies examining topics related to TAVR from late-breaking sessions at TCT Connect 2020. 

Tsuyoshi Kaneko, MD: Perspective on TAVR Data at TCT Connect 2020

Results of the SCOPE II trial from TCT Connect offer insight into the head-to-head comparison of ACURATE neo valve versus the CoreValve Evolut R System. 

ACURATE neo Valve Fails to Demonstrate NonInferiority vs CoreValve Evolut in SCOPE II

Results of REDUCE-IT PCI detail a 34% reduction in 5-point MACE and a 39% reduction in total events among patients receiving icosapent ethyl (Vascepa) in the original trial with a history of PCI.

REDUCE-IT PCI Details Benefits of Icosapent Ethyl in Patients with History of PCI

Results from 3-year follow-up of the ULTIMATE study indicate IVUS-guided PCI was associated with lower rates of TVF and stent thrombosis. 

ULTIMATE Details 3-Year Benefit of IVUS-Guided PCI vs Angiography-Guided PCI

A trial presented at TCT 2020 suggests crushed prasugrel provided no reperfusion benefit when compared against integral tablet in STEMI patients. 